9EP Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Very High Gross MarginA roughly 98% gross margin shows that Enanta’s offerings can generate substantial value after direct costs. If its pipeline produces commercially viable medicines or partnered products, this underlying economics could support attractive contribution margins, even though current operating expenses still exceed gross profit.
Improved LeverageThe sharp reduction in debt and return to a much lower debt-to-equity level improve financial flexibility relative to prior periods. Positive equity and less leverage give Enanta more capacity to fund development, manage volatility, and pursue partnerships while reducing balance-sheet pressure.
Losses Are NarrowingAlthough Enanta remains unprofitable, the narrowing of losses suggests some improvement in the relationship between revenue and operating spending. Continued progress could extend its cash runway and reduce the financing burden, making future pipeline investment more sustainable if the trend persists.
Bears Say
Persistent Operating LossesDeep operating and net losses indicate that Enanta’s current business activities do not yet cover its cost base. Sustained unprofitability can erode equity, constrain investment in research programs, and increase dependence on successful partnerships, milestones, or future external financing.
Ongoing Cash BurnNegative operating and free cash flow show that Enanta is not currently self-funding its operations. Even with improved burn versus earlier periods, continued cash consumption can reduce financial flexibility and make advancement of its pipeline dependent on reserves, partnerships, or capital access.
Patent Ruling Weakens IP LeverageThe European patent invalidation removes a potential source of enforcement leverage and licensing proceeds connected with Paxlovid. It also highlights the difficulty of monetizing disputed intellectual property against a large competitor, weakening the value of this potential revenue opportunity.
Enanta Pharmaceuticals News
9EP FAQ
What was Enanta Pharmaceuticals’s price range in the past 12 months?
Currently, no data Available
What is Enanta Pharmaceuticals’s market cap?
Enanta Pharmaceuticals’s market cap is CHF266.53M.
When is Enanta Pharmaceuticals’s upcoming earnings report date?
Enanta Pharmaceuticals’s upcoming earnings report date is Nov 16, 2026 which is in 16 days.
How were Enanta Pharmaceuticals’s earnings last quarter?
Enanta Pharmaceuticals released its earnings results on Aug 10, 2026. The company reported -CHF0.55 earnings per share for the quarter, missing the consensus estimate of -CHF0.419 by -CHF0.131.
Is Enanta Pharmaceuticals overvalued?
According to Wall Street analysts Enanta Pharmaceuticals’s price is currently Undervalued.
Does Enanta Pharmaceuticals pay dividends?
Enanta Pharmaceuticals does not currently pay dividends.
What is Enanta Pharmaceuticals’s EPS estimate?
Enanta Pharmaceuticals’s EPS estimate is -0.59.
How many shares outstanding does Enanta Pharmaceuticals have?
Enanta Pharmaceuticals has 29,125,402 shares outstanding.
What happened to Enanta Pharmaceuticals’s price movement after its last earnings report?
Enanta Pharmaceuticals reported an EPS of -CHF0.55 in its last earnings report, missing expectations of -CHF0.419. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Enanta Pharmaceuticals?
Currently, no hedge funds are holding shares in CH:9EP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Enanta Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
CHF16.41 (― Upside)
CHF16.41 (― Upside)
Blogger Sentiment
Neutral
CH:9EP Sentiment 67%
Sector Average 64%
Sector Average 64%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
4.89%
12-Months-Change
Fundamentals
Return on Equity
-61.84%
Trailing 12-Months
Asset Growth
-1.38%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Enanta Pharmaceuticals
Enanta Pharmaceuticals, Inc. is a biotechnology firm dedicated to discovering and advancing small molecule therapies designed to combat a range of viral infections and various liver conditions. Its research and development efforts are primarily focused on addressing pathogens such as respiratory syncytial virus (RSV), SARS-CoV-2, human metapneumovirus (hMPV), and the hepatitis B virus (HBV). The company also holds a strategic partnership and licensing agreement with Abbott Laboratories. This collaboration involves the joint identification, development, and market introduction of specific HCV NS3 and NS3/4A protease inhibitor compounds, including known agents like paritaprevir and glecaprevir, which are utilized in the management of chronic hepatitis C virus. Founded in 1995, Enanta Pharmaceuticals, Inc. operates from its principal office located in Watertown, Massachusetts.
9EP Stock 12 Month Forecast
Average Price Target
―Abeona Therapeutics
―
Tectonic Therapeutic
―
Allogene Therapeutics
―
Jade Biosciences
―
Neumora Therapeutics, Inc.
―